What are the recommended daily doses, mechanisms of action, common adverse effects, fixed-dose combination formulations, and treatment regimens for first-line anti‑tuberculosis drugs according to Indian guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Daily Doses of Anti-Tuberculosis Drugs According to Indian Guidelines

The standard daily regimen for drug-susceptible TB in India consists of 2 months intensive phase with Isoniazid (5 mg/kg or 300 mg), Rifampicin (10 mg/kg or 600 mg), Pyrazinamide (25 mg/kg or 1500 mg), and Ethambutol (15 mg/kg or 800-1200 mg), followed by 4 months continuation phase with Isoniazid and Rifampicin at the same doses. 1

Daily Dosing Schedule

India transitioned from thrice-weekly to daily dosing in 2015, following WHO recommendations 2. The current daily doses are:

Intensive Phase (2 months):

  • Isoniazid: 5 mg/kg (typically 300 mg for adults)
  • Rifampicin: 10 mg/kg (typically 600 mg for adults)
  • Pyrazinamide: 25 mg/kg (typically 1500 mg for adults)
  • Ethambutol: 15 mg/kg (typically 800-1200 mg for adults)

Continuation Phase (4 months):

  • Isoniazid: 5 mg/kg (typically 300 mg)
  • Rifampicin: 10 mg/kg (typically 600 mg)

Pyridoxine (vitamin B6) 10-25 mg/day must be given with Isoniazid to all patients at risk of neuropathy, including pregnant women, breastfeeding mothers, HIV-positive patients, diabetics, alcoholics, malnourished patients, those with chronic renal failure, and elderly patients. 1

Mechanisms of Action

Isoniazid (INH)

Inhibits mycolic acid synthesis by blocking InhA enzyme, disrupting mycobacterial cell wall formation. It is bactericidal against actively dividing organisms.

Rifampicin (RIF)

Inhibits bacterial DNA-dependent RNA polymerase, preventing RNA transcription. It is bactericidal and has sterilizing activity against both actively dividing and semi-dormant organisms.

Pyrazinamide (PZA)

Converted to pyrazinoic acid in acidic pH, disrupting membrane energetics and transport functions. It is particularly effective against semi-dormant bacilli in acidic environments.

Ethambutol (EMB)

Inhibits arabinosyl transferase enzymes, blocking arabinogalactan synthesis in the mycobacterial cell wall. It is bacteriostatic and prevents emergence of resistance to companion drugs.

Common Adverse Effects

Hepatotoxicity (Most Common with INH, RIF, PZA)

  • Mechanism: Oxidative stress, mitochondrial dysfunction, cytochrome P450 induction 3
  • Risk factors: Advanced age, malnutrition, pre-existing liver disease, NAT2 slow acetylator status
  • Management: Monitor baseline and serial liver function tests; discontinue temporarily if ALT >3× ULN with symptoms or >5× ULN asymptomatic 3
  • Incidence: Drug-induced hepatitis occurred in 5.6% of patients in recent Indian cohort 4

Peripheral Neuropathy (INH)

  • Mechanism: Pyridoxine depletion disrupting nerve function 3
  • Prevention: Pyridoxine 25-50 mg/day (increase to 100 mg/day if neuropathy develops) 5

Optic Neuritis (EMB)

  • Mechanism: Copper chelation leading to optic nerve damage 3
  • Monitoring: Monthly visual acuity and color vision testing
  • Management: Discontinue EMB immediately if vision changes occur

Gastrointestinal Effects

  • Common: Gastritis (29.2%), vomiting (27.5%), nausea (21.9%) in Indian patients 4
  • Peak incidence: First 2 months of treatment
  • Management: Symptomatic treatment; most resolve without drug discontinuation

Other Notable Effects

  • Skin rashes: 12.5% incidence 4
  • Myelosuppression: Primarily RIF-related, monitor CBC 3
  • CNS toxicity: INH-induced seizures due to GABA disruption 3

Fixed-Dose Combinations (FDCs)

FDCs are strongly recommended in Indian guidelines as they minimize selective drug intake, reduce pill burden, and improve adherence. 1

Available FDC Formulations:

  • 4-drug FDC (Intensive Phase): H(75mg) + R(150mg) + Z(400mg) + E(275mg)
  • 3-drug FDC (Intensive Phase): H(75mg) + R(150mg) + Z(400mg)
  • 2-drug FDC (Continuation Phase): H(75mg) + R(150mg)

Dosing is weight-based using standardized weight bands, simplifying administration and reducing errors.

Treatment Regimens

Standard Regimen (Category I - New Cases)

2HRZE / 4HR - Given daily under DOTS (Directly Observed Treatment, Short-course) 1

Category II (Previously Treated Cases)

2HRZES / 1HRZE / 5HRE - Includes Streptomycin in intensive phase

Special Populations

Pregnancy: All first-line drugs except Streptomycin can be used safely. Streptomycin causes fetal ototoxicity and is contraindicated. Pyridoxine 10 mg/day is mandatory. 1

Diabetes: Same regimen as non-diabetics, but strict glucose control is essential. Rifampicin increases clearance of oral hypoglycemics, requiring dose adjustments. 1

HIV Co-infection: Standard short-course chemotherapy is indicated. Response is good but relapse rates are higher. Rifampicin interacts with protease inhibitors and NNRTIs, requiring careful ART selection. 1

Renal Failure: Adjust doses of Streptomycin, Ethambutol, and Isoniazid based on creatinine clearance. In acute renal failure, give Ethambutol 8 hours before hemodialysis. 1

Pre-existing Liver Disease: If liver enzymes are normal, all drugs may be used with frequent LFT monitoring. 1

Critical Monitoring Parameters

Baseline assessments: LFTs, CBC, creatinine, visual acuity (if using EMB), HIV testing 3

During treatment:

  • Monthly sputum smear and culture (where feasible)
  • LFTs at 2,4, and 8 weeks, then as clinically indicated
  • Monthly visual assessments if on Ethambutol
  • CBC if symptoms of myelosuppression
  • Clinical assessment at each DOTS visit

Treatment success in Indian cohorts: 96.3% of patients with ADRs achieved successful outcomes with proper management 4, demonstrating that most adverse effects can be effectively managed without compromising treatment success.

Common Pitfalls to Avoid

  1. Failing to prescribe pyridoxine with Isoniazid in high-risk patients leads to preventable neuropathy
  2. Not monitoring vision monthly in patients on Ethambutol can result in irreversible optic damage
  3. Continuing hepatotoxic drugs when ALT >5× ULN risks acute liver failure
  4. Using Streptomycin in pregnancy causes permanent fetal hearing loss
  5. Inadequate dose adjustment in children and HIV-positive patients leads to treatment failure 6

The evidence strongly supports daily dosing over intermittent regimens for better outcomes, and FDCs are the preferred formulation to ensure adherence and prevent acquired drug resistance 1, 2.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.